Structural insights into interaction mechanisms of alternative piperazine-urea YEATS domain binders in MLLT1
preprint
OA: closed
AI-generated summary
Crystal structures reveal that piperazine-urea derivatives bind MLLT1's YEATS domain via different mechanisms than benzimidazole-amides, offering an alternative targeting strategy.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
ABSTRACT YEATS-domain-containing MLLT1 is an acetyl/acyl-lysine reader domain, which is structurally distinct from well-studied bromodomains and has been strongly associated in development of cancer. Here, we characterized piperazine-urea derivatives as an acetyl/acyl-lysine mimetic moiety for MLLT1. Crystal structures revealed distinct interaction mechanisms of this chemotype compared to the recently described benzimidazole-amide based inhibitors, exploiting different binding pockets within the protein. Thus, the piperazine-urea scaffold offers an alternative strategy for targeting the YEATS domain family.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00